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Introduction: The purpose of pulmonary metastasectomy is to
remove all known remaining cancer with the purpose of cure or to
lengthen survival. Little information is available on the extent of
surgery that is justified and or on reasonable evidence based limits
to the extent of surgery.
Methods: A systematic review was designed to evaluate the role of
extended surgery in the treatment of lung metastasis. For this
analysis, the following three research questions were formulated.
Q1) Is pneumonectomy indicated for pulmonary metastasectomy?
Q2) What is the number of repeat operations justified and what
might be the criteria?
Q3) What number of individual metastases is it justified to remove
in a single procedure? A MEDLINE search of English language
articles was conducted using key words appropriate to the three
questions posed. We excluded reports with little or no data,
single cases, small series, and review articles without data.
Results: Most information concerning extremes of surgery is in the
form of case reports, small series, or sporadic cases within a
retrospective report of a larger group of patients undergoing pulmo-
nary metastasectomy. Meta-analysis was ruled out because of the
insufficient quantity and quality of data in the available literature.
Q1) extended resection for pulmonary metastasis is feasible and may
be justified in individualized circumstances. We believe caution
is warranted before performing pneumonectomy because it is
debatable whether any possible benefit justifies the adverse
consequences of this surgery and long-term survival is poor.
Q2) multiple attempts to re-establish intrathoracic control of meta-
static disease supported by some authors in carefully selected
patients, but apparent benefit may be a result of survivor bias,
and the ratio of harm to benefit is likely to increase with each
subsequent attempt.
Q3) if on accepted criteria specific to the primary cancer the patient
is a candidate for pulmonary metastastasecomy, then the goal
should be to resect all metastases that are there, irrespective of
the number. However, with increasing pulmonary metastatic
count, there is less good survival and greater loss of lung tissue.
These issues should be fully considered at the planning stage.
Conclusions: Evidence-based recommendations for extended treat-
ment of lung metastasis are at best weak. We have summarized the
available data to provide the most up to date information regarding
extended surgery in an attempt to define limits in the treatment of
lung metastasis.
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The purpose of pulmonary metastasectomy, with few ex-ceptions, is to achieve cure or to lengthen survival, by
removing all known remaining cancer for that patient. It is
usually undertaken in the absence of symptoms attributable to
metastatic disease so other than in individual and uncommon
circumstances metastasectomy is not undertaken with pallia-
tive intent. The commonest cancer for which pulmonary
metastasectomy is performed is colorectal cancer and in a
systematic review1 and in registry data.2 R0 versus R1 resec-
tion has been shown to be associated with longer survival.
Given that background information, surgeons naturally
should strive for complete (R0) resection.
In a survey of practice, which revealed considerable
variation, 74% of surgeon rated predictable failure to achieve
complete resections as an absolute contraindication to pul-
monary metastasectomy. A further 24% regarded it as a
relative contraindication leaving only 2% who did not regard
this as an obstacle.3
In clinical practice, when a patient with cancer devel-
ops lung metastasis the first question that occurs may well be
“how long will I survive”. There is a survival difference
between those who have R0 resection and those who have
residual disease after metastasectomy, and because surgery is
offered with a prospect of cure, it seems obvious to think that
extended resection should play an important role in achieving
long-term survival in this unfortunate group of patients. Does
it succeed in that objective? In the absence of conclusive
evidence (which would be provided in an ideal world by a
randomized trial), it is possible that apparent longer survival
is product of case selection rather than surgical eradication.4
Nevertheless, the practice of pulmonary metastasectomy is
widespread,3 and in many countries it is increasing.
There is a paradox to be considered in introducing this
subject. In follow-up studies with sufficient cases of both
types, a formal anatomic resection (such as lobectomy) is
associated with lower 5-year survival rates than wedge resec-
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tions (25% versus 39%) so more is not better in this instance.1
In clinical practice, limited resection when possible to pre-
serve lung parenchyma is nowadays the preferred method to
perform metastasectomy. Nevertheless, we have noted that
the role of extended resection for pulmonary metastasectomy
is still unclear, and very poor information is available in the
English literature on the extent of resection for lung metas-
tasis. The purpose of this review is to explore the issues to
help inform surgical practice.
DEFINITIONS
For the purposes of this article, we consider “extended
resection” to be an operation beyond the usual limits of com-
monplace practice, which is to perform local nonanatomic resec-
tion, of one, two, or three metastases, on one occasion.
Y In the context of pulmonary metastasectomy, we will
consider radical anatomic resection, specifically pneu-
monectomy, to be extended resection.
Y We know from large numbers of case series that resec-
tion of one to three metastases is by far the commonest
surgery and most patients with colorectal cancer have
just one metastasis removed (Figure 1). So resection of
say more than three, whether by multiple wedges or by
precision techniques can also be considered for the
purposes of this analysis, as in the realm of extended
resection.
FIGURE 1. Percentage of patients
with multiple metastases. (Adapted
from J R Soc Med.20)
FIGURE 2. Percentage of patients
having repeat pulmonary metasta-
sectomy. (Adapted from J R Soc
Med.20)
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Y Repeated operations can also be considered as extending
the practice of pulmonary metastasectomy (Figure 2).
One should note that for the purposes of the registry,
Pastorino5 allowed planned sequential thoracotomy to
remove bilateral mestastasectomy as a single metasta-
sectomy episode.
METHODS
The basic evidence-based analysis was designed to
evaluate the role of extended surgery in the treatment of lung
metastasis. For this analysis, the following three research
questions were formulated:
1. Q1 Is pneumonectomy indicated?
2. Q2 What are the actual criteria and limitations for the
number of repeated resections?
3. Q3 What is the number of multiple resection justified in
a single procedure?
In this article, we address these three in turn.
Literature Search Criteria
A MEDLINE search of English language articles was
conducted using simple key words that included for Q1,
metastasectomy and pneumonectomy; for Q2, lung or pul-
monary and repeated and metastasectomy; and for Q3, me-
tastasectomy and multiple resection. Criteria for exclusion
were review articles, manuscripts which did not reported
series of more than five patients, or insufficient outcome data
to be useful.
RESULTS
Q1 Is Pneumonectomy Indicated?
Pneumonectomy entails removal of the whole of one
lung. Every pneumonectomy is associated with major phys-
iological changes and any substantial reported series includes
deaths and serious complications. It is probably a fair starting
point that pneumonectomy has therefore only been performed
for metastatic cancer if there are compelling reasons in that
the cancer seems to be otherwise eradicated and the patient
is very fit. The technical indications to resort to pneumo-
nectomy to treat lung metastasis are typically for a very
large metastasis or a metastasis critically involving hilar
structure such that the surgeon cannot clear the cancer and
leave a viable lung. There is therefore an inherent (a
clinically appropriate) bias in the selection of cases enter-
ing any data set.
Very few series concerning primary or completion pneu-
monectomy were found. We were left with seven for consider-
ation, six of which are in the Table 1,2,6–10 one of them used
twice for primary and completion pneumonectomy.
We found two reports of experience with pneumonec-
tomy performed specifically for lung metastasectomy.2,6
Most reports of pneumonectomy for lung metastasis are case
reports or within a large experience of lung metastasectomy,
and generally little information is available on long-term
survival. Most patients do not survive more than 2 years and
the best reported 5-year survival data are in the International
Registry of Lung Metastases (IRLM) data.2
Completion pneumonectomy implicitly represents an
operation performed as a last chance of cure from lung
metastasis when previous lung metastasectomy has already
been performed. The indications for completion pneumonec-
tomy are the presence of a single central lesion or absence of
enough lung tissue to obtain a free resection margin after one
or more previous operation for lung metastasis. The reports
are heterogeneous, some from (IRLM) data2 and some from
a series of completion pneumonectomy operations for a
mixture of benign and malignant indications.10
It has been claimed in IRLM data that there is a better
long-term survival after completion pneumonectomy for lung
metastasis than primary pneumonectomy.2 This conclusion
cannot really be drawn from our evidence table. There are too
few cases, and the difference is not striking. There are
probably two factors involved in creating this impression.
One is the degree of fitness that would be required to put a
patient forward for this surgery. The other is the survivor
selection: the patient has survived long enough after the
primary and after the first metastasectomy to be in a favorable
TABLE 1. Evidence Table Showing Mortality and 5-yr Survival in Patients Undergoing
Pneumonectomy or Completition Pneumonectomy for Lung Metastasis
Authors Date Range No. of Patients Mortality (%) Outcome 5-yr Survival (%)
Primary pneumonectomy
Spaggiari et al.6 1985–1995 42a 7 17
Koong et al.7 1962–1994 R0 112; R1 21 4; 19 23
Completion pneumonectomy
Putnam et al.8 1981–1992 19 11 25
Grunenwald et al.9 1985–1995 12 8 10
Koong et al.7 1962–1994 38 3 30
Jungraithmayr et al.10 1986–2003 9 0 b
Chataigner et al.11 1996–2005 11 0 41
a The data include primary pneumonectomy, completion pneumonectomy, and contralateral pneumonectomy for recurrence after
metastasectomy.
b The data given imply that none have so far survived 5 yr. There was one recurrence free survivor 9 mo after surgery at the time of
writing.
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biologic group. Only patients with unusually indolent cancers
will represent as candidates and remain under consideration
for metastasectomy after the rigorous work up required in
such unusual circumstances.
Anecdotally reported pneumonectomy results include
publication bias (people are less likely to report their most
disappointing outcomes). Consequently, the data reported are
not predictive of what might be the outcome in future patients
and this caveat should be born in mind if pneumonectomy
were to be offered more liberally. On the basis of such
information, Pairolero commenting on Spaggiari et al.6 sug-
gested that pneumonectomy for lung metastasis should, with
specific exceptions, be avoided.
Q2 Criteria for and Number of Repeated
Resections
Recurrence of lung metastasis is not uncommon, and
repeated resections are undertaken in an attempt to control the
disease. In the clinical practice of a thoracic surgeon, it is not
unusual that patients who experiences recurrent resectable
lung metastases, and are found to remain free of disease at the
primary location, are likely to be sent back to the thoracic
surgeon for further surgery. There are plentiful accounts of
patients who remain well for some time, or indefinitely after
a second or subsequent reoperation for metastasectomy.
Therefore, the question of how many repeated resection
should be performed to achieve long-term survival is con-
crete, but still with some controversy.
Twenty-two publications have been found, of those 19
have been excluded on the basis of the title or the abstract.
That left seven articles and, two more articles have been
added from other resources (Table 2).
Multiple repeat resections are predominately used in
sarcoma and colorectal surgery and tend to be reported in
series of younger patients.
In patients with sarcoma, after repeated metastasectomy,
the 3-year actuarial survival rate was 31%, and repeated resec-
tion was found to be an independent prognostic factor for
survival.11 In addition, Tronc et al. in pediatric patients with
sarcoma suggest that repeat metastasectomy can salvage a subset
of patients who retain favorable prognostic determinants:
namely apparent complete resection was achieved and that there
were few metastases to resect.12 Temeck et al.13 found a differ-
ence in median survival for resectable versus unresectable me-
tastasis after a second, third, and fourth thoracotomy (5.6 versus
0.7 years, 5.2 versus 2.5 years, 2.2 versus 0.2 years, respec-
tively). There was also a negative influence on survival associ-
ated with the number of preoperative nodules. The presence of
two or more metastases in a recurrent case was associated with
a poor survival of 20% at 5 years versus 60% if only one
recurrent metastasis was present.13 This finding is important
because recurrent multiple metastasis is associated with poor
long-term survival; “extended” operation should not be advo-
cated in this unfortunate subgroup of patients.
Patients who are persistently free of disease at the
primary location but who have recurrent, resectable meta-
static disease of the lung are considered likely to benefit from
operation a second, third, or even fourth time.14 The first two
metastasectomies more than 40 months (imprecisely referred
to by the authors as the disease-free interval (DFI) is associ-
ated with significantly longer survival, P  0.0012). On the
other hand, a DFI less than 6 months between the first two
metastasectomies is associated with negative prognosis and
should therefore limit the promptness of surgical resection.
Another important point to clarify is the circumstance
when the recurrent metastasis develops in the controlateral
lung; there is no evidence that there is a difference in
prognosis between recurrent metastases in the operated lung
compared with the contralateral side.
Patients with osteosarcoma persistently free of primary
osteosarcoma who developed recurrent resectable metastatic
disease of the lung have similar DFI curves at 5 years. Park et
al.15 found that of the 10 patients who received a third metasta-
sectomy, overall survival was 78% at 5 years after last operation,
and Jaklitsch et al.16found that that where there had beenmultiple
attempts to re-establish intrathoracic control of metastatic disease,
the magnitude of benefit decays with each subsequent attempt.
Q3 Number of Metastases Resected in a Single
Procedure
It is not uncommon that more than 40 metastasis have
been removed in a single procedure in patients with sarcoma.
Biology of the tumor and the presence of resectable
metastatic disease confined to the lungs must be taken in
TABLE 2. Evidence Table Showing 5-yr Survival After Repeated Operations for Lung
Metastases
Author Dates of Series No. of Patients Pathology 5-yr Survival
Temeck et al.13 1965–1995 70 Sarcoma 52a
IRLM, Pastorino5 1945–1995 Not stated Mixed 44
Kandioler et al.14 1973–1993 330 Mixed 48
Jaklitsch et al.16 1988–1998 54 Mixed 57
Liebl et al.21 1990–2005 42 Sarcoma 40.5
Welter et al.22 1993–2003 33 Colorectal 53.8
Tronc et al.12 1995–2006 25 Paediatric 25
Park et al.15 1995–2007 10 Colorectal 75
Chen et al.11 1989–2007 14 Sarcoma 19
References for Table 2 are not cited in the metastases. Liebl et al. and Welter et al.21,22
a Data taken from the Kaplan Meier survival curve.
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account when multiple metastases are present. In patients
with resectable lung metastases from sarcoma it is argued that
“in patients with resectable pulmonary metastases from sar-
coma or carcinoma, the number of metastases should have little
influence on the surgical decision, except for delaying this
decision in patients with several metastases until a significant
interval, with or without treatment, has shown that metastatic
disease remains resectable and confined to the lungs.”17
Precision laser technique has been used to remove
multiple lung metastases.18 Rolle et al. after removing 3267
nodules in 328 patients with a mean of 10 nodules/patient
reported a 5-year survival of 28% for 10 metastases removed
and 26% for 20 or more metastases. But note, none of 44
patients with three or more lung metastases of colorectal
cancer and DFI less than 1 year was cured from the opera-
tion,19 and surgery when metastases are both recurrent and
multiple is associated with poor long-term survival.13 The
claims for benefit for resection of larger numbers of metas-
tases are within retrospective studies in which most patients
have few metastases. Those operated on with many multiple
metastases will have a range of other factors considered,
which are likely to have been more favorable than average to
allow them to have been selected for surgery. Multivariate
analysis will probably not have made a complete statistical
adjustment.
COMMENT AND SUMMARY
Making evidence-based recommendations for extended
treatment of lung metastasis is challenging for a number of
reasons. The cases are usually a minority within the total
patients in the follow-up study. Meta-analysis is not possible
due to the insufficient quality of the available literature.
It is clear that the decision to perform an extended
metastasectomy it is not just a demonstration of surgical
ability but has other clinical motives. The aspiration of the
surgeon to achieve long-term survival for patients remains the
most significant. To accomplish this objective, several factors
must be taken in consideration such as histology and biology
of the tumor, DFI, number, size and position of the metasta-
ses, laterality, and recurrence. A combination of these factors is
sometimes of great importance, in fact for instance multiple
recurrent lung metastases are associated with poor long term
survival and therefore extended surgery should be discouraged.
The choice of nonanatomic (laser precision technique
or wedge resection) versus anatomic resection (segmentec-
tomy, lobectomy, and pneumonectomy) depends on the pa-
tient’s lung function, position, number, size, and position of
the metastases. As the evidence supporting pneumonectomy
is poor, a surgeon before undertaking pneumonectomy or
completion pneumonectomy for lung metastasis should have
a frank and detailed discussion with the patient and relatives.
Q1 Extended resection for pulmonary metastasis is feasible
and may be justified in individualized circumstances. We believe
caution is warranted before performing pneumonectomy because it
is debatable whether any possible benefit justifies the adverse
consequences of this surgery and long term survival is poor.
Recurrent metastasectomy poses recurrent difficulties
in decision making. An aggressive approach to pulmonary
metastases of sarcomas is justified by experts as repeated
resections have demonstrated prolonged survival. Recurrent
metastasectomy is not advocated in presence of multiple lung
nodules and the magnitude of benefit decays with each
subsequent attempt.
Q2 Multiple attempts to re-establish intrathoracic con-
trol of metastatic disease is supported by some authors in
carefully selected patients, but apparent benefit may be a
result of survivor bias and the ratio of harm to benefit is likely
to increase with each subsequent attempt.
If multiple lung metastases are to be removed no matter
what their number, consideration should be given to the
histology and the biologic behavior of the tumor, the DFI, and
the quantity lung tissue which will be lost.
Q3 If on accepted criteria specific to the primary cancer the
patient is a candidate for pulmonary metastastasecomy, then the
goal should be to resect all metastases that are there, irrespective of
the number. However, with increasing pulmonary metastatic count
there is less good survival and greater loss of lung tissue. These
issues should be fully considered at the planning stage.
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